Study of SC-101 for advanced cancers with NECTIN4 gene changes
Part of Cancer, Skin clinical trials.
This trial tests a new drug called SC-101 for people with advanced cancers that have a specific genetic change called NECTIN4 amplification. The drug targets this genetic change to try to stop the cancer from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have advanced cancer that has the NECTIN4 gene change (your doctor can test for this)
- You are generally able to take care of yourself (ECOG 0-1)
- You have not had serious side effects from previous treatments that haven't gone away
- Your organs and blood counts are good enough for the trial
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental oral drug (NKT5097) for people with advanced solid tumors that have not responded to other treatments. It may also be an option for people with a specific type of breast cancer (HR+/HER2-). The goal is to see if the drug is safe and effective.
This trial is testing whether a blood test can track how well chemotherapy is working in people with early-stage triple-negative breast cancer. You would provide blood samples before and during treatment, and the results may help your doctor understand your response better.
This trial tests a new drug called SC-101 in people with advanced solid tumors that have not responded to other treatments. It may be an option if your tumor shows a specific protein called Nectin-4, which the drug targets.
This trial tests a new drug called SC-102 in people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if SC-102 is safe and how well it works.
This trial tests a new drug, CRB-701, for people with advanced solid tumors that have a protein called nectin-4 on their surface. It might be an option if other treatments have stopped working or are not available.
This trial tests an experimental drug (LNF2105) for people with advanced solid tumors that have stopped responding to standard treatment. The drug targets a protein called Nectin-4 on cancer cells, and participating could give you access to a new option while helping to evaluate its safety.
Hear when a new HR+ Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.